SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Go AS, Hilek M, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implication for rhythm management and stroke prevention: the anticoagulation and Risk Factors in Atria Fibrillation (Atria) Study. JAMA 2001; 285: 23705.
  • 2
    Fuster V, Rydèn LE, Cannom SD, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association; European Society of Cardiology. [ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary. Eur Heart J 2006; 27: 19792030.
  • 3
    Ptsaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 245561.
  • 4
    Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, Sebaoun A for the College of French Cardiologists. Characterization of different subset of atrial fibrillation in general practice in France: the ALFA study. Circulation 1999; 99: 302835.
  • 5
    Pristowsky EN. Tachycardia-induced tachycardia: a mechanism of initiation of atrial fibrillation. In: Atrial Arrhythmias: State of Art, eds Di MarcoJP, PristowskyEN. Armonk, NY: Futura, 1995.
  • 6
    Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new onset AF atrial fibrillation. JAMA 2004; 292: 24717.
  • 7
    Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 144957.
  • 8
    Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risk associated with atrial fibrillation: 20 year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 35964.
  • 9
    Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 47684.
  • 10
    Le Heuzey JY, Paziaud O, Piot O, Said MA, Copie X, Lavergne T, Guize L. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004; 147: 1216.
  • 11
    Freudenberger RS, Wilson AC, Kostis JB. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J. Cardiol 2007; 100: 24752.
  • 12
    Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacologic Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet 2000; 356: 178994.
  • 13
    Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodelling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 135564.
  • 14
    Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993; 27: 3418.
  • 15
    Hanatani A, Yoshiyama M, Kim S, Omura T, Toda I, Akioka K, Teragaki M, Takeuchi K, Iwao H, Takeda T. Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. J Mol Cell Cardiol 1995; 27: 190514.
  • 16
    Lie JT, Falk RH, James TN. Cardiac anatomy and pathologic correlates of atrial fibrillation. In: Atrial Fibrillation: Mechanisms and Management, 2nd edn, eds FalkRH, PodridPJ. Philadelphia, PA: Lippincott-Raven, 1997; 2352.
  • 17
    Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 11814.
  • 18
    Goette A, Arndt M, Rocken C, Spiess A, Staack T, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101: 267881.
  • 19
    Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 260814.
  • 20
    Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 80920.
  • 21
    Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocyte and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 1993; 73: 41323.
  • 22
    Okazaki H, Minamino T, Tsukamoto O, Kim J, Okada K, Myoishi M, Wakeno M, Takashima S, Mochizuki N, Kitakaze M. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition. Hypertens Res 2006; 29: 27782.
  • 23
    Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G, Kottkamp H, Gummert JF, Dhein S. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003; 42: 178592.
  • 24
    Everett THIV, Li H, Mangrum JM, McRury ID, Mitchell MA, Redick JA, Haines DE. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 2000; 102: 145460.
  • 25
    Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodelling in atrial fibrillation. Circulation 2000; 101: 26127.
  • 26
    Zankov DP, Omatsu-Kanbe M, Isono T, Toyoda F, Ding WG, Matsuura H, Horie M. Angiotensin II potentiates the slow component of delayed rectifier K+ current via the AT1 receptor in guinea pig atrial myocytes. Circulation 2006; 113: 127886.
  • 27
    Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, Moore JH, Hsu KL, Tseng CD, Liau CS, Tseng YZ. Renin–angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004; 109: 16406.
  • 28
    Gensini F, Padeletti L, Fatini C, Sticchi E, Gensini GF, Michelucci A. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 2003; 26 (1 Pt 2): 2958.
  • 29
    Ogimoto A, Hamada M, Nakura J, Miki T, Hiwada K. Relation between angiotensin converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy. J Hum Genet 2002; 47: 1849.
  • 30
    Darbar D, Motsinger A, Ritchie MD, Gainer JV, Roden DM. ACE I/D polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm 2007; 4: 7439.
  • 31
    Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32: 695703.
  • 32
    Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 2003; 107: 292631.
  • 33
    Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 37638.
  • 34
    Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, De Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 20: 61116.
  • 35
    Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester PO, Hedner T, De Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 20: 17516.
  • 36
    Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 7129.
  • 37
    Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 70512.
  • 38
    Maggioni AP, Latini R, Peter E, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, Cohn JN; Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 5485.
  • 39
    Ducharme A, Swedber K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S; CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 8692.
  • 40
    Madrid HA, Bueno MG, Rebollo JM, Marín I, Peña G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C. Use of irbesartn to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 3318.
  • 41
    Dagres N, Karatasakis G, Panou F, Athanassopoulos G, Maounis T, Tsougos E, Kourea K, Malakos I, Kremastinos DT, Cokkinos DV. Pre-treatment with irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation. Eur Heart J 2006; 27: 20628.
  • 42
    Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, Dai Y, Su L, Ling Z, She Q, Luo K, Woo K, Dong J. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27: 18417.
  • 43
    Madrid HA, Marin IM, Cervantes CE, Morell EB, Estévez JE, Moreno G, Parajón JR, Peng J, Limón L, Nannini S, Moro C. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of Angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5: 11420.
  • 44
    Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-lasting persistent atrial fibrillation: results of a prospective and controlled study. Eur Heart J 2003; 24: 20908.
  • 45
    Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Coll Cardiol 2005; 45: 18329.
  • 46
    Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol 2006; 46: 218.
  • 47
    Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006; 152: 21722.
  • 48
    Fazio G, Pizzuto C, Sutera L, Guttilla D, Di Gesaro G, Cascio C, Novo G, Assennato P, Novo S. Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart. Minerva Cardioangiol 2007; 55: 31115.
  • 49
    Teo K, Yusuf S, Seight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H; ONTARGET/TRASCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 5261.
  • 50
    ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 154759.
  • 51
    Connolly S, Yusuf S, Budaj A, Camm J, Chrolavicius S, Commerford PJ, Flather M, Fox KA, Hart R, Hohnloser S, Joyner C, Pfeffer M, Anand I, Arthur H, Avezum A, Bethala-Sithya M, Blumenthal M, Ceremuzynski L, De Caterina R, Diaz R, Flaker G, Frangin G, Franzosi MG, Gaudin C, Golitsyn S, Goldhaber S, Granger C, Halon D, Hermosillo A, Hunt D, Jansky P, Karatzas N, Keltai M, Lanas F, Lau CP, Le Heuzey JY, Lewis BS, Morais J, Morillo C, Oto A, Paolasso E, Peters RJ, Pfisterer M, Piegas L, Pipillis T, Proste C, Sitkei E, Swedberg K, Synhorst D, Talajic M, Trégou V, Valentin V, Van Mieghem W, Weintraub W, Varigos J. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J 2006; 151: 118793.
  • 52
    Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G; GISSI-AF Investigators. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med (Hagerstown) 2006; 7: 2938.